MannKind : First Quarter 2024 Earnings Call Presentation

1Q 2024 Earnings Call

May 8, 2024

© Copyright 2024. All rights reserved. MannKind Corporation.

Cautionary Statement

This presentation includes forward-looking statements relating to, without limitation, our future commercial growth and pipeline advancement, our ability to commercialize pharmaceutical products, statements regarding the commencement of clinical studies of MNKD-101 and MNKD-201, and the data read-outs from clinical studies of Afrezza and MNKD-201. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks associated with manufacturing and supply, risks associated with developing product candidates, stock price volatility and other risks detailed in our filings with the Securities and Exchange Commission ("SEC"), including under the "Risk Factors" heading our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 27, 2024. You are cautioned not to place undue reliance on these forward-looking statements. which speak only as of the date of this presentation. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this presentation.

2 © Copyright 2024. All rights reserved. MannKind Corporation.

Today's Agenda

Operational and	Michael Castagna, CEO
Pipeline Highlights
Financial Review	Steven B. Binder, EVP &
Former CFO
Additional Comments	Michael Castagna, CEO
Analyst Q&A

3 © Copyright 2024. All rights reserved. MannKind Corporation.

Michael Castagna

Chief Executive Officer

4 © Copyright 2024. All rights reserved. MannKind Corporation.

Our mission is to give people control of their health and the freedom to live life.

5 © Copyright 2024. All rights reserved. MannKind Corporation.

1Q 2024 Highlights

Orphan Lung

Diseases

UT: Tyvaso DPI

MNKD Pipeline

• Record royalty revenue of $22.7M (+94%) and record manufacturing-related revenues of $24.8M (+118%)
• MNKD-101 (clofazimine inhalation susp): FDA Fast Track Designation; FDA clearance for IND; expect Phase 3 registrational trial ICoN-1 to start in 2Q
• MNKD-201 (nintedanib DPI): FDA clearance to proceed to Ph1 trial; expect Phase 1 trial to start in 2Q

Endocrine

Diseases

Financial

• 1Q Afrezza net revenue of $14.4M: +16% vs. 2023
• Afrezza INHALE-1:26-week top line results expected by EOY

Endo BU • Afrezza INHALE-3

• • • Positive first meal dosing results presented at ATTD in March
    • 17-weektop-line results at ADA in June
  • India - Subject Expert Comm recommended permission to import & market
• GAAP Net income of $11M
• Ended 1Q24 with $304M in cash, cash equivalents and investments (+$2M vs. 4Q)
• Repaid MidCap senior secured debt and Mann convertible debt first week of April

6 © Copyright 2024. All rights reserved. MannKind Corporation. / 8 May 2024

NTM: MNKD-101

Clofazimine Inhalation

Suspension

7 © Copyright 2024. All rights reserved. MannKind Corporation. / 8 May 2024

NTM prevalence is increasing over time and market will likely exceed $1Billion by end of decade with two players

NTM Epidemiology

NTM Patients per Year

1. K

1. K

1. K

1. K

1. K

1. K

1. K

													223
												212
									202
								193
					183
			175
	166
159

122 131 141 151 162 175 188 202

234

217

246

233

258

251

• 2022 NTM disease prevalence of 122K

and 159K patients in the U.S. and Japan

• The prevalence rate of NTM is increasing

globally

• Within the U.S., claims-based studies

suggest an annual NTM prevalence

CAGR of 7.5%1

• NTM prevalence and CAGRs suggest a

2032 prevalence of >500K patients in

Japan and U.S.

NTM Prevalence	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032
(K)
	159	166	175	183	193	202	212	223	234	246	258
Japan
U.S.	122	131	141	151	162	175	188	202	217	233	251

8

1 Winthrop. An Am Thorac Soc.2020.

ICoN-1 Ph 3 Study Design - Cleared to Proceed by FDA; FDA Fast-TrackDesignation Received

Screening

Treatment Cycle 1 Treatment

Treatment Cycle 2 Treatment

OLE

Day	Day
84	168

	End of 28		End of 28
MNKD-101 + GBT	Day Dosing	Off Period	Day Dosing
QD	QD
Patients on GBT for
min 6 months
Placebo + GBT

Alignment with the FDA on co-primary endpoints:

• Sputum conversion
• Patient Reported Outcomes

Phase 3 study expected to enroll first patient in June 2024 Orphan + QIDP designation (potential 12 years exclusivity)

Off Period

EOT

Primary Endpoint

Interim

Analysis at

50% patients

9 © Copyright 2024. All rights reserved. MannKind Corporation.

Pulmonary Fibrotic Diseases:

MNKD-201

Nintedanib DPI

10 © Copyright 2024. All rights reserved. MannKind Corporation. / 8 May 2024